Express Pharma

Four-in-10 patients fear pharma supply chain issues pose risk of illness and death

Ninety five per cent of the industry decision-makers in the APAC region seek better cooperation between government/regulatory agencies and pharma companies

0 126

Zebra Technologies Corporation has released the findings of its pharmaceutical supply chain vision study. It reveals patients’ distrust of the medications they are receiving and segments within the pharma supply chain, including the entities who manufacture, distribute, prescribe and dispense those drugs. Forty-three percent fear more illness and/or death could result from contaminated or tainted medications without supply chain improvements.

The study was conducted among a global audience of over 3,500 patients and pharma industry decision makers to evaluate perceived supply chain stability, gauge supply chain responsibility and trust in its entities, and identify needs for improving supply chain visibility and transparency.

Medication efficacy and safety are top of mind today with patients with three-in-four patients stating they are either somewhat or very concerned about the ineffectiveness of medication in helping with their condition or illness. Moreover, seven-in-10 are concerned about receiving an improper dose due to labelling errors, and the harm it could potentially cause them; stolen, contaminated, tainted, expired, or counterfeit medicines; and medications that were improperly handled/stored during transit and could have damaged or diminished efficacy.

Patients know a compromised supply chain puts medication quality and efficacy at risk and want better assurances that their medications are safe and authentic. Nine-in-10 say it is somewhat or very important that they can verify a medication is not counterfeit or tampered with, and confirm temperature-sensitive medications have stayed within the prescribed range.

According to the survey, patients also expect drug manufacturers to disclose how their medications are manufa